About Assertio
Assertio is a company based in Lake Forest (United States) founded in 1995. The company has 58 employees as of December 31, 2024. Assertio has completed 2 acquisitions, including OTREXUP and Spectrum Pharmaceuticals. Assertio offers products and services including Pharmaceutical Products and Business Development Services. Assertio operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Lake Forest, United States
- Employees 58 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Assertio Therapeutics, Inc
-
Annual Revenue
$124.96 M (USD)-17.83as on Dec 31, 2024
-
Net Profit
-$21.58 M (USD)93.5as on Dec 31, 2024
-
EBITDA
$8.96 M (USD)-83.15as on Dec 31, 2024
-
Latest Funding Round
$575 M (USD), Debt – Conventional
Mar 12, 2015
-
Investors
Oxford Finance
& 10 more
-
Employee Count
58
as on Dec 31, 2024
-
Investments & Acquisitions
OTREXUP
& 1 more
-
Acquired by
(Apr 08, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Assertio
Assertio is a publicly listed company on the NASDAQ with ticker symbol ASRT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Assertio
Assertio offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Business Development Services.
Products for patient treatment and adverse event reporting
Services for partnerships and investor engagement
People of Assertio
Unlock access to complete
Funding Insights of Assertio
Investors in Assertio
Assertio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Finance, HBM Healthcare Investments and Biovail.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Lumira Ventures is engaged in life sciences venture capital investment.
|
Locked | Locked | Locked |
Investor details for Assertio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Assertio
Assertio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OTREXUP and Spectrum Pharmaceuticals.
Investment portfolio details for Assertio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Methotrexate injections are offered via the official Otrexup website.
|
Locked | Locked | 2012 | Locked | |
|
Small molecule therapeutics for oncology and hematology are developed.
|
Locked | Locked | 1987 | Locked |
Complete acquisition details for Assertio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Assertio
Detailed financials for Assertio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Assertio Comparisons
Peer comparison for Assertio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Assertio
Assertio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Pain treatment products are developed through reformulation technologies.
|
Detailed competitors of Assertio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Assertio
Complete news archive for Assertio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Assertio
Assertio was founded in 1995 and raised its 1st funding round 3 years after it was founded.
Assertio is headquartered in Lake Forest, United States. It is registered at Lake Forest, California, United States.
As of Dec 31, 2024, the latest employee count at Assertio is 58.
Annual revenue of Assertio is $124.96M as on Dec 31, 2024.
Developer of drugs to treat pain and other neurological diseases. It offers Nucynta ER indicated for the management of pain associated with diabetic peripheral neuropathy (DPN), Gralise for the management of postherpetic neuralgia (PHN), Cambia for acute treatment of migraine attacks, Lazanda for the management of breakthrough pain in cancer patients; and Zipsor, liquid filled capsules for relief of mild to moderate acute pain. Its pipeline developing drugs include cebranopadol, analgesic for the treatment of moderate to severe chronic nociceptive and neuropathic pain.
Assertio's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Assertio offers Pharmaceutical Products and Business Development Services.
Yes, Assertio is publicly traded on NASDAQ under the ticker symbol ASRT.
Assertio has made 2 acquisitions, including OTREXUP, and Spectrum Pharmaceuticals.
Assertio has 11 investors. Key investors include Oxford Finance, HBM Healthcare Investments, Biovail, Deerfield, and GE Healthcare Equipment Finance.
The ticker symbol of Assertio is ASRT on NASDAQ.